Tag

Glp 1

All articles tagged with #glp 1

healthcare2 hours ago•10 min saved

Vivani pursues long-acting GLP-1 implant to boost adherence

Vivani Medical is developing a tiny, under-the-skin implant that releases semaglutide to provide steady GLP-1 drug exposure for obesity/diabetes treatment, aiming to improve long-term adherence and potentially reduce side effects. The device uses a membrane with millions of microchannels to deliver a consistent dose over months, with a long-term goal of biannual or annual dosing. The first human trial, SLIM-1, is expected to begin mid-2026 in Australia, comparing implants to a low-dose Wegovy injection; if safe and effective, later studies would define dosing and regulatory approval. Key questions remain on comparative efficacy, tolerability, cost, insurance coverage, and how easily providers will adopt in practice; Novo Nordisk is collaborating but not licensing at this stage.

via CNBC|

#glp-1 #healthcare #implant

business1 day ago•19 min saved

GLP-1 Fallout: Ozempic Side Effects Fuel Billion-Dollar Lawsuits

A surge in GLP-1 drugs like Ozempic for weight loss has spurred thousands of lawsuits alleging serious gastrointestinal injuries and vision loss, with potential damages reaching billions; regulators say shortages have eased, while manufacturers defend the drugs’ safety.

via Dallas Express|

#business #gastroparesis #glp-1

sports1 day ago•10 min saved

GLP-1 Weight-Loss Drugs: Athletes May Lose More Than Weight

Athletes using GLP-1 weight-loss drugs may shed pounds but can see negative effects on performance, including higher resting heart rate and lower HRV; early research suggests fat loss must be balanced with preserved muscle, adequate nutrition, and training, because appetite suppression can trigger energy deficiency (RED-S). The author recommends structured meals, pre-workout fueling, a rough 3:1 carb-to-protein intake, and checking vitamin D and B12 levels, with wearables guiding adjustments. Long-term effects are still unknown, and athletes are helping to build the data.

via Men's Health|

#athletes #glp-1 #hrv

health2 days ago•8 min saved

DIY Lipo Craze Sparks Safety Alarm Over At-Home Fat-Dissolving Kits

A New York Post exposé highlights a rising DIY “lipo” trend where budget-minded women self-inject unregulated fat-dissolving solutions bought online, after prior weight loss with GLP-1 meds. Proponents claim dramatic contouring at a fraction of liposuction’s cost, but experts warn the practice is unsafe: injections can cause permanent scarring, infections, nerve or tissue damage, and other serious complications. The piece centers on Ruth, who used a $95 kit to treat multiple areas and reports visible results, illustrating both the allure and danger of at-home fat dissolution, as medical professionals advocate FDA-approved options and professional supervision instead.

via New York Post|

#cosmetic-surgery #diy-lipo #glp-1

health3 days ago•4 min saved

Orforglipron tops oral GLP-1 rivals in 52-week diabetes trial

A 52-week Phase 3 trial in 1,698 adults with type 2 diabetes found that Eli Lilly’s orforglipron, an oral small‑molecule GLP-1 drug, reduced HbA1c by about 1.71–1.91 percentage points and produced greater weight loss (6.1–8.2 kg) compared with oral semaglutide (1.47 HbA1c reduction and ~5.3 kg weight loss). However, tolerability favored semaglutide, with around 59% reporting GI side effects on orforglipron versus 37–45% on semaglutide and higher discontinuation (~10% vs ~4–5%). Orforglipron’s small‑molecule, no‑refrigeration profile could improve access in lower‑income countries, but there’s no head‑to‑head with injectable GLP‑1s yet and long‑term adherence remains to be seen.

via ScienceDaily|

#glp-1 #hba1c #health

business3 days ago•3 min saved

Employer Hesitancy Keeps GLP-1 Obesity Drugs Largely Uncovered, Survey Finds

An IFEBP survey shows most U.S. employers haven’t expanded GLP-1 obesity-drug coverage. About 36% provide GLP-1 coverage for both diabetes and weight loss (up from 2024), 60% cover diabetes only, and roughly 45% cover GLP-1s for other conditions. Cost remains the main driver, with plans restricting coverage or directing employees to direct-to-consumer options or HSAs/FSA dollars. Employers emphasize existing benefits like disease management and nutrition counseling, and only around 9% are considering obesity coverage. Medicare’s 18-month obesity coverage rollout could shift decisions if real-world savings materialize.

via CNBC|

#business #employer-coverage #glp-1

health3 days ago•15 min saved

GLP-1 Weight-Loss Drugs Now Used by 11% of Americans

A Gallup poll of 5,065 U.S. adults (May 28–June 5, 2026) finds 11% are currently using GLP-1 weight‑loss drugs (up from 8% in 2025), with 15% having ever tried them and 91% having heard of them; the trend follows FDA approvals for Wegovy (2021) and Zepbound (2023) and coincides with ongoing, but not universal, changes in obesity rates (self‑reported around the mid‑30s). Most users report brand-name drugs, though some use compounded versions; side effects like nausea are possible, while some data suggest reduced cravings, and oral Wegovy (approved 2025) signals more delivery options in the future.

via Gizmodo|

#gallup #glp-1 #health

health3 days ago•11 min saved

US GLP-1 Weight-Loss Use Surges to New High Amid Obesity Decline

Gallup’s 2026 Health & Well-Being Index shows 11% of U.S. adults currently use GLP-1 weight-loss drugs (up from 3% in 2024) and 15% have used them ever. Brand-name meds account for 68% of current use, with compounded versions rising to 19% as cost/insurance influence switching. Awareness of GLP-1s is 91%. The obesity rate has declined to 36.4% in 2026, while diabetes rates remain steady, suggesting GLP-1 uptake may be linked to obesity declines. About one-third of compounded users switched from brand-name, mainly for cost reasons. Data come from 5,065 adults surveyed May 28–June 5, 2026.

via Gallup News|

#brand-name #diabetes #glp-1

health4 days ago•21 min saved

Secret shoppers reveal minimal medical oversight for online GLP-1 weight-loss scripts

A Yale secret-shopping study in which a Yale medical student posed as a 237-pound patient found that most online GLP-1 weight-loss drug vendors provide lax clinical oversight; only 13 of 49 sites required video consultations, with many relying on unverified online questionnaires, raising patient-safety concerns amid the GLP-1 drug boom.

via The Washington Post|

#glp-1 #health #healthcare-regulation

health7 days ago•20 min saved

Retatrutide’s online boom tests the edges of legality

A Washington Post feature describes how people are buying the weight-loss peptide retatrutide online, highlighting safety concerns and an unclear regulatory status, making it a popular but not clearly legal or regulated consumer option.

via The Washington Post|

#glp-1 #health #legality

health8 days ago•7 min saved

GLP-1s for Addiction: Early Signals, Still Many Questions

Glucagon-like peptide-1 receptor agonists, originally used for diabetes and obesity, are being explored as addiction treatments. Early data from animal studies, observational research, and some randomized trials suggest GLP-1s may dampen reward-driven cravings and reduce alcohol consumption, with semaglutide showing reductions in craving and heavy drinking in alcohol use disorder; results for opioid, cocaine, and nicotine use disorders are less robust and mostly preclinical. The drugs likely act on shared brain reward pathways and may broadly decrease reward seeking, not just addiction-specific cravings. Many critical questions remain about which patients benefit, optimal dosing and duration, durability after stopping, interactions with comorbidities, and equitable access. Large, longer-term trials are ongoing, and GLP-1s are not yet ready to replace established addiction treatments.

via Medscape|

#addiction #alcohol-use-disorder #glp-1

health8 days ago•61 min saved

MassHealth ends GLP-1 obesity coverage, affecting thousands statewide

MassHealth will stop covering GLP-1 weight‑loss medications starting Friday, affecting about 22,000 Medicaid beneficiaries (including roughly 2,500 children). Coverage remains for diabetes or obesity with certain medical conditions. The move is projected to save about $15 million but risks weight regain and worsened health for those losing access, leaving some to go without treatment, pay out of pocket, or seek cheaper alternatives; under‑21 coverage remains only with medical necessity.

via The Boston Globe|

#glp-1 #health #masshealth

health-policy9 days ago•7 min saved

Medicare's $50 GLP-1 Plan Targets Seniors, But With Limitations

Medicare launches an 18-month GLP-1 Bridge program outside Part D to offer eligible beneficiaries $50-a-month copays for certain weight‑loss drugs (Foundayo tablets, Wegovy, Zepbound) ending Dec 31, 2027. Eligibility is based on BMI and specific health conditions, and prescriptions can be issued even if the doctor doesn’t take Medicare, but some diabetics and individuals with sleep apnea or fatty liver may still face higher costs under Part D. Medicare covers about $245 of the drug cost minus the $50 copay, potentially leaving a total outlay of up to roughly $900 over 18 months for a participant, with no low-income subsidy. Total taxpayer cost is projected at $1.3 billion to $10 billion depending on uptake. The program could boost access but may strain clinics and lacks long-term funding certainty.

via Bridge Michigan|

#glp-1 #health-policy #medicare

health9 days ago•7 min saved

GLP-1 Drugs Show Systemic Effects Beyond Weight Loss in June 2026 Studies

Four observational studies published in June 2026 suggest GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) may affect more than glucose and weight: roughly 30% lower odds of breast cancer in users, a weakened impulsivity-to-violence link linked to brain GLP-1 receptors, a possible bone-protective effect despite weight loss, and a significant drop in daily physical activity among users. None establish causation; findings require randomized trials and do not change current indications. Clinicians should emphasize exercise and bone health monitoring, and patients should not start/stop meds based on these early results. Larger prospective studies are needed to confirm these associations.

via Medical Daily|

#bone-health #breast-cancer #diabetes

health10 days ago•23 min saved

GLP-1 Weight-Loss Revolution: What Science Says About Benefits, Side Effects, and Longevity

Stanford Medicine explains GLP-1 agonists (semaglutide/Ozempic/Wegovy and tirzepatide/Mounjaro/Zepbound) work by slowing gastric emptying and boosting satiety to reduce intake and improve insulin. On average, semaglutide yields about 15% weight loss and tirzepatide about 20%, but responses vary widely and some people lose little weight. Side effects are mainly gastrointestinal and usually transient, though long-term safety data are still evolving. Weight loss typically slows after 4–6 months, with a fuller plateau by 12–18 months; stopping these meds often leads to regain, so many clinicians view GLP-1s as long-term therapies, sometimes alongside lifestyle changes or bariatric surgery. Pediatric use exists but requires caution and specialist guidance. Insurance coverage and cost remain practical hurdles to access.

via Stanford Medicine|

#glp-1 #health #obesity